The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Experts Discuss 3 Frequently Overlooked Syndromes

Experts Discuss 3 Frequently Overlooked Syndromes

March 15, 2021 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ME/CFS 

Dr. Komaroff

Dr. Komaroff

Another disorder rheumatologists should look out for is myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), said Anthony Komaroff, AB, MD, MA (Hon), senior physician, Brigham and Women’s Hospital, Boston, and Steven P. Simcox, Patrick A. Clifford and James H. Higby Distinguished Professor of Medicine, Harvard Medical School, Boston. ME/CFS is defined as a substantial impairment in the ability to function for more than six months, along with a new, profound fatigue not relieved by rest, malaise after exertion, unrefreshing sleep, cognitive impairment and/or orthostatic intolerance. People with ME/CFS tend to have scores on tender point exams halfway between normal and what appears in fibromyalgia. The condition often starts with an infectious illness. 

You Might Also Like
  • Study Finds Chronic Fatigue Clues in Overactive Immune Response
  • Osteoporosis Experts Discuss Bisphosphonate Holidays
  • Scientists May Be Closer to A Blood Test for Chronic Fatigue Syndrome
Explore This Issue
March 2021
Also By This Author
  • Lupus Nephritis: New Decade, New Approaches

Many features of ME/CFS overlap with fibromyalgia, including fatigue and headaches. But in ME/CFS, several abnormalities of the central nervous system (CNS) tend to appear, such as neuro­endocrine dysfunction, cognition problems and magnetic resonance imaging abnormalities. ME/CFS is also marked by immune activation, including elevated cytokine levels, increased circulating activated CD8-positive cells and autoantibodies against CNS antigens. 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Metabolic studies have found a general downregulation of metabolic products as well as impairment of energy metabolism, Dr. Komaroff said.1 

An emerging theory posits ME/CFS is the “sickness symptoms hypothesis,” in which during acute illness, a group of neurons called the fatigue nucleus orches­trates a reduction in energy consuming activities to preserve energy stores to fight the illness. One likely trigger of the fatigue nucleus is neuroinflammation that continues even though the inciting antigen is wiped out. Alternatively, in some people, the activated fatigue nucleus gets stuck in the on position, causing sickness symptoms to continue, Dr. Komaroff said. 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“There remain many important unanswered questions in this illness, but the increasing interest and support from NIH and CDC in studying it, I hope, [will] provide some more fundamental answers in the coming years,” he said. 

MCAS

Dr. Schwartz

Dr. Schwartz

A mast cell activation syndrome (MCAS) diagnosis includes clinical presentation of systemic ana­phylaxis, elevated mast cell bio­markers, a response to anti-mast cell-mediator or activation therapies, and possibly, inherited or acquired genetic traits, said Lawrence Schwartz, MD, PhD, the Charles and Evelyn Thomas Professor of Medicine and chair of the Division of Rheumatology, Allergy and Immunology, Virginia Commonwealth University, Richmond.

Systemic anaphylaxis involves a rapid onset of illness involving two or more of the following systems: skin, gastrointestinal, respiratory or cardio­vascular. Its lifetime prevalence among adults ranges from 2–8%, according to phone surveys, so there is a need for biomarkers for precise diagnosis, said Dr. Schwartz. 

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

During systemic anaphylaxis, tryptase (which accounts for 10–20% of the entire protein in a mast cell, but with no pharmacotherapy that blocks its production) has a half-life of about two hours in circulation after its secretion by activated mast cells. This is longer than other commercially available biomarkers, so it can be useful in diagnosing MCAS. But a baseline level must be available, because a clinically significant rise in acute tryptase levels is defined as 1.2 times the baseline level, plus 2 ng/mL. 

“An acute tryptase level by itself isn’t helpful,” Dr. Schwartz said. 

Somatic gain-of-function mutations of the c-kit gene or an inherited genetic trait underlie many MCAS cases, he said. Increased copies of the protein coding gene TPSAB1, when that gene encodes alpha-tryptase, can enhance alpha-tryptase expression, known as hereditary alpha-tryptasemia.2 

Dr. Schwartz added that cases without a known cause could involve dysregulation of other pathways involved in mast cell activation.

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: ACR Convergence 2020, mast cell activation syndrome (MCAS), myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS), postural orthostatic tachycardia syndrome (POTS)Issue: March 2021

You Might Also Like:
  • Study Finds Chronic Fatigue Clues in Overactive Immune Response
  • Osteoporosis Experts Discuss Bisphosphonate Holidays
  • Scientists May Be Closer to A Blood Test for Chronic Fatigue Syndrome
  • MRI & Axial Spondyloarthritis: Experts Discuss Controversies in the Diagnostic Evaluation of axSpA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)